CN Patent

CN119301125A — Akr1c3依赖性kars抑制剂的晶型

Assigned to Novartis AG · Expires 2025-01-10 · 1y expired

What this patent protects

本申请涉及AKR1C3依赖性KARS抑制剂的晶型。(式I)

USPTO Abstract

本申请涉及AKR1C3依赖性KARS抑制剂的晶型。(式I)

Drugs covered by this patent

neratinib-maleate (NERATINIB MALEATE)

Patent Metadata

Patent number: CN119301125A
Jurisdiction: CN
Classification: —
Expires: 2025-01-10
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.